Vericiguat suppresses ventricular tachyarrhythmias inducibility in a rabbit myocardial infarction model
Open Access
- 16 April 2024
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (4) , e0301970
Abstract
Background: The VICTORIA trial demonstrated a significant decrease in cardiovascular events through vericiguat therapy. This study aimed to assess the potential mechanisms responsible for the reduction of cardiovascular events with vericiguat therapy in a rabbit model of myocardial infarction (MI). Methods: A chronic MI rabbit model was created through coronary artery ligation. Following 4 weeks, the hearts were harvested and Langendorff perfused. Subsequently, electrophysiological examinations and dual voltage-calcium optical mapping studies were conducted at baseline and after administration of vericiguat at a dose of 5 μmol/L. Results: Acute vericiguat therapy demonstrated a significant reduction in premature ventricular beat burden and effectively suppressed ventricular arrhythmic inducibility. The electrophysiological influences of vericiguat therapy included an increased ventricular effective refractory period, prolonged action potential duration, and accelerated intracellular calcium (Cai) homeostasis, leading to the suppression of action potential and Cai alternans. The pacing-induced ventricular arrhythmias exhibited a reentrant pattern, attributed to fixed or functional conduction block in the peri-infarct zone. Vericiguat therapy effectively mitigated the formation of cardiac alternans as well as the development of reentrant impulses, providing additional anti-arrhythmic benefits. Conclusions: In the MI rabbit model, vericiguat therapy demonstrates anti-ventricular arrhythmia effects. The vericiguat therapy reduces ventricular ectopic beats, inhibiting the initiation of ventricular arrhythmias. Furthermore, the therapy successfully suppresses cardiac alternans, preventing conduction block and, consequently, the formation of reentry circuits.Keywords
Funding Information
- Chang Gung Medical Foundation (CMRPG3L1202)
- Ministry of Science and Technology, Taiwan (110-2314-B-182A-119-)
This publication has 30 references indexed in Scilit:
- 2022 ACC/AHA/HFSA Guideline for the Management of Heart FailureJournal of Cardiac Failure, 2022
- Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjectsEuropean Journal of Clinical Pharmacology, 2020
- Cardiac optical mapping – State-of-the-art and future challengesThe International Journal of Biochemistry & Cell Biology, 2020
- Sacubitril/Valsartan vs. Angiotensin Receptor Inhibition in Heart Failure: A Real-World Study in TaiwanESC Heart Failure, 2020
- Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction ModelJournal of Cardiac Failure, 2020
- cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathwayBasic Research in Cardiology, 2018
- Sudden Cardiac Death From the Perspective of Coronary Artery DiseaseMayo Clinic Proceedings, 2014
- Modulation of cardiac ERG1 K+ channels by cGMP signalingJournal of Molecular and Cellular Cardiology, 2010
- Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytesJournal of Molecular and Cellular Cardiology, 2009
- Antiarrhythmic effect of carvedilol after acute myocardial infarctionJACC, 2005